Who Paid My Doc
Jeffrey Teuteberg
Advanced Heart Failure and Transplant Cardiology Stanford, CA Medical Doctor
NPI 1952377582 CMS profile 270380
300 Pasteur Dr, Stanford, CA 94305
General payments
$195,072
Research payments
$4,600
Ownership & investment interest
$0
Research they led as principal investigator
$22,730
Through program year 2025, Jeffrey Teuteberg of Stanford, CA is reported in the CMS Open Payments database as having received $195,072 across 304 general payments and $4,600 in research payments paid to them. Separately, studies naming them as principal investigator received $22,730 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 92nd percentile of Advanced Heart Failure and Transplant Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
12 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $53,050 | 85 | |
| 2024 | General | $22,761 | 47 | |
| 2024 | Research | $250 | 1 | |
| 2023 | General | $5,940 | 15 | |
| 2022 | General | $17,567 | 27 | |
| 2022 | Research | $250 | 1 | |
| 2021 | General | $38,439 | 62 | |
| 2021 | Research | $1,500 | 2 | |
| 2020 | General | $17,218 | 13 | |
| 2020 | Research | $600 | 1 | |
| 2019 | General | $40,097 | 55 | |
| 2019 | Research | $2,000 | 2 |
Beside peers
- Jeffrey Teuteberg
- Advanced Heart Failure and Transplant Cardiology median
- Middle half of Advanced Heart Failure and Transplant Cardiology
- National median
In program year 2025, general payments to Jeffrey Teuteberg were reported at $53,050. Among 967 Advanced Heart Failure and Transplant Cardiology profiles paid that year, the median was $1,024 and the middle half received between $289 and $6,890.
Show as a table
| Year | Jeffrey Teuteberg | Advanced Heart Failure and Transplant Cardiology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $40,097 | $863 | $224–$4,562 | $163 |
| 2020 | $17,218 | $452 | $122–$3,992 | $114 |
| 2021 | $38,439 | $550 | $159–$3,571 | $132 |
| 2022 | $17,567 | $729 | $221–$4,357 | $149 |
| 2023 | $5,940 | $1,002 | $309–$5,827 | $160 |
| 2024 | $22,761 | $931 | $273–$5,204 | $164 |
| 2025 | $53,050 | $1,024 | $289–$6,890 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 38 drugsPart D claims
1,972
Drug cost
$442,371
Branded share of claims
16.7%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Entresto Sacubitril/Valsartan | Brand | 121 | $159,591 | |
| Jardiance Empagliflozin | Brand | 77 | $102,622 | |
| Eliquis Apixaban | Brand | 34 | $44,096 | |
| Farxiga Dapagliflozin Propanediol | Brand | 46 | $37,667 | |
| Everolimus | Generic | 13 | $26,155 | |
| Zarxio Filgrastim-Sndz | Brand | 11 | $25,991 | |
| Sirolimus | Generic | 51 | $15,107 | |
| Tacrolimus | Generic | 97 | $6,001 | |
| Mycophenolate Mofetil | Generic | 47 | $4,083 | |
| Cyclosporine Modified Cyclosporine, Modified | Brand | 14 | $3,215 |
The 10 drugs with the highest cost, of 38 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 24 billing codesPaid by Medicare
$76,854
Medicare patients
489
Services billed
941
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Heart failure | 62% | |
| Chronic kidney disease | 56% | |
| Ischemic heart disease | 54% | |
| Diabetes | 51% | |
| Atrial fibrillation | 51% | |
| Arthritis | 39% | |
| Depression | 28% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
311 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Advanced Heart Failure and Transplant Cardiology in California
Richard Wright
Advanced Heart Failure and Transplant Cardiology · Santa Monica, CA
James Heywood
Advanced Heart Failure and Transplant Cardiology · La Jolla, CA
Hirsch Mehta
Advanced Heart Failure and Transplant Cardiology · San Diego, CA
Teresa De Marco
Advanced Heart Failure and Transplant Cardiology · San Francisco, CA
Rajeev Mohan
Advanced Heart Failure and Transplant Cardiology · La Jolla, CA
Marcus Urey
Advanced Heart Failure and Transplant Cardiology · San Diego, CA
Related records
Advanced Heart Failure and Transplant Cardiology in California
Practitioners in the same specialty and state, ranked by reported value.
All Advanced Heart Failure and Transplant Cardiology
Everyone recorded under this specialty, nationwide.
Doctors in California
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.